Myelodysplastic Syndromes and Myelodysplastic Syndromes/Myeloproliferative Neoplasms: A Real-World Experience From a Developing Country
JCO Global Oncology · 2024-02 · (10)
DOI: 10.1200/go.23.00281 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCO Global Oncology, 2024-02. Verfasst von Abdalla Awidi und 11 weiteren Autor:innen. Beteiligte Einrichtung: Medical School, University of Jordan, Amman, Jordan. Hauptthemen laut MEDLINE: Myelodysplastic Syndromes, Leukemia, Myeloid, Acute. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCATS NIH HHS.
Abstract (Originalsprache)
PURPOSE Myelodysplastic syndromes (MDS) include a heterogeneous group of clonal bone marrow disorders characterized by ineffective hematopoiesis. They manifest as dysplasia in bone marrow hemopoietic elements associated with peripheral cytopenias with variable risk of AML transformation. PATIENTS AND METHODS We analyzed retrospectively registry data collected prospectively from patients with primary MDS and patients with MDS/myeloproliferative neoplasm (MPN) in the Jordan University Hospital between January 2007 and September 2021. The registry captured epidemiologic information such as date of diagnosis, age, gender, date of AML transformation, cytogenetics, MDS subtype, risk group according to Revised International Prognostic Scoring System, and survival. The registry also captured baseline ferritin, B12, and lactate dehydrogenase levels. RESULTS A total of 112 patients with MDS and MDS/MPN were included in the registry. Median age at diagnosis was 59 years. The male-to-female ratio was about 1.2. In a multivariate cox regression model, baseline serum ferritin significantly affected survival as patients with levels exceeding 1,000 μg/L had a risk of death three times higher compared with those with
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Medical School, University of Jordan, Amman, Jordan.
- Jordan University Hospital, Amman, Jordan.
- Cell Therapy Center, University of Jordan, Amman, Jordan.
- Al-Basheer Hospital, Ministry of Health, Amman, Jordan.
- Yale Cancer Center and Smilow Cancer Hospital, Yale University School of Medicine, New Haven, CT.
ORCID-Profile: Abdalla Awidi, Nada Odeh, Jawad Alrawabdeh, Muntaser Al Zyoud, Hisham Bawa'neh, Amer M Zeidan
Förderung
- NCATS NIH HHS
Zitieren
APA
Awidi, A., Alzu'bi, M., Odeh, N., Alrawabdeh, J., Al Zyoud, M., Hamadneh, Y., Bawa'neh, H., Magableh, A., Alshorman, A., Al-Fararjeh, F., Aladily, T., & Zeidan, A. M. (2024). Myelodysplastic Syndromes and Myelodysplastic Syndromes/Myeloproliferative Neoplasms: A Real-World Experience From a Developing Country. JCO Global Oncology. https://doi.org/10.1200/go.23.00281
Vancouver
Awidi A, Alzu'bi M, Odeh N, Alrawabdeh J, Al Zyoud M, Hamadneh Y, et al. Myelodysplastic Syndromes and Myelodysplastic Syndromes/Myeloproliferative Neoplasms: A Real-World Experience From a Developing Country. JCO Global Oncology. 2024. doi:10.1200/go.23.00281
BibTeX
@article{Awidi2024,
author = {Awidi, Abdalla and Alzu'bi, Marah and Odeh, Nada and Alrawabdeh, Jawad and Al Zyoud, Muntaser and Hamadneh, Yazan and Bawa'neh, Hisham and Magableh, Ahmad and Alshorman, Alaa and Al-Fararjeh, Feras and Aladily, Tariq and Zeidan, Amer M},
title = {Myelodysplastic Syndromes and Myelodysplastic Syndromes/Myeloproliferative Neoplasms: A Real-World Experience From a Developing Country},
journal = {JCO Global Oncology},
year = {2024},
number = {10},
doi = {10.1200/go.23.00281}
}
EUVIMED